introduct
aim
studi
demonstr
express
keratinocyt
psoriat
lesion
comparison
keratinocyt
uninvolv
skin
studi
chang
express
therapeut
intervent
materi
method
studi
includ
patient
differ
clinic
subtyp
psoriasi
gene
express
analysi
perform
use
real
time
quantit
pcr
three
biopsi
obtain
patient
two
taken
lesion
psoriat
skin
uninvolv
skin
start
treatment
third
lesion
skin
biopsi
taken
end
month
treatment
treatment
form
topic
steroid
oral
system
methotrex
result
studi
patient
significantli
increas
express
note
keratinocyt
psoriat
lesion
treatment
compar
keratinocyt
uninvolv
skin
p
p
respect
express
skin
lesion
treatment
significantli
lower
lesion
skin
treatment
p
psoriat
skin
lesion
studi
patient
express
significantli
correl
diseas
durat
r
p
clinic
sever
psoriasi
r
p
conclus
increas
express
keratinocyt
psoriat
lesion
patient
correl
diseas
durat
sever
support
concept
psoriasi
cell
mediat
autoimmun
diseas
could
establish
therapeut
prevent
approach
psoriasi
ultim
lead
improv
outcom
patient
psoriasi
chronic
inflammatori
condit
result
persist
stimul
cell
antigen
epiderm
origin
persist
stimul
cell
result
interact
cell
antigenpres
cell
ie
langerhan
cell
antigen
compris
follow
step
primari
signal
signal
includ
tcell
receptor
stimul
peptid
antigen
costimul
socal
accessori
signal
signal
helper
type
differenti
prolifer
propos
cytokin
releas
activ
tlymphocyt
initi
maintain
psoriat
process
stimul
keratinocyt
prolifer
sinc
time
becom
clear
hanaa
rasmi
nanci
mikhael
somaia
ismail
upon
stimul
keratinocyt
also
abl
secret
array
differ
cytokin
varieti
function
effect
cell
type
includ
tlymphocyt
interleukin
il
relat
famili
term
structur
function
receptor
level
activ
take
place
signal
chain
put
receptor
complex
first
describ
induc
factor
gener
induct
similar
sole
cytokin
induc
low
level
presenc
costimul
product
greatli
enhanc
howev
antibodi
also
reduc
hepatotox
endotoxaemia
consid
possess
biolog
properti
beyond
induc
activ
cell
synthes
gmcsf
also
report
suppress
product
induc
product
gener
abil
induc
differ
cytokin
depend
cellular
target
flisiak
et
al
confirm
associ
plasma
concentr
psoriasi
sever
moreov
shown
combin
measur
plasma
consid
possibl
biomark
psoriasi
activ
kato
et
al
indic
singl
nucleotid
polymorph
snp
promot
gene
associ
presenc
psoriasi
atop
dermat
suggest
snp
associ
suscept
psoriasi
vulgari
presum
affect
product
studi
analys
express
psoriasi
vulgari
much
less
inform
avail
abil
differ
therapeut
intervent
modul
ongo
chang
express
chronic
disord
especi
human
diseas
psoriasi
aim
studi
demonstr
express
keratinocyt
psoriat
lesion
comparison
keratinocyt
nonlesion
skin
studi
chang
express
therapeut
intervent
studi
includ
patient
patient
select
outpati
clinic
benha
univers
hospit
alhaud
almarsoud
nation
research
center
cairo
egypt
patient
includ
women
men
age
rang
year
mean
year
differ
clinic
subtyp
psoriasi
exhibit
variou
degre
sever
histori
present
ill
includ
onset
cours
durat
previou
treatment
date
last
topic
applic
system
therapi
inclus
criteria
includ
studi
adult
psoriat
patient
year
old
receiv
topic
therapeut
modal
apart
petrolatum
last
week
system
therapi
last
week
presenc
absenc
coexist
noncutan
condit
establish
three
patient
hypertens
psoriat
arthropathi
hepat
c
viru
hcv
anaemia
chronic
disord
type
diabet
mellitu
hypertens
posit
famili
histori
encount
one
case
two
patient
upper
respiratori
tract
infect
cold
exposur
worsen
patient
clinic
present
sweat
aggrav
patient
condit
patient
psychogen
factor
precipit
case
studi
patient
affect
predispos
factor
psoriasi
area
sever
index
pasi
score
sheet
adopt
accord
fredriksson
pettersson
mark
et
al
patient
indic
degre
sever
mild
case
extent
diseas
exceed
sever
case
extent
diseas
base
pasi
score
inform
consent
obtain
complet
descript
studi
particip
accord
guidelin
local
ethic
committe
nation
research
center
two
biopsi
taken
patient
first
set
first
biopsi
taken
lesion
psoriat
skin
second
nonlesion
skin
patient
subject
continu
treatment
form
topic
steroid
oral
system
methotrex
followup
month
six
patient
moder
sever
degre
psoriasi
palmoplantar
subtyp
psoriasi
respond
topic
steroid
receiv
oral
system
methotrex
dosag
use
mg
per
week
three
divid
dose
taken
interv
period
folat
supplement
patient
receiv
system
methotrex
subject
monitor
liver
blood
test
monthli
eight
patient
mild
moder
degre
psoriasi
maintain
topic
steroid
cream
ointment
form
betamethason
dipropion
twice
daili
end
cours
third
psoriat
lesion
skin
biopsi
taken
patient
prevent
degrad
intracellular
rnase
tissu
embed
soon
excis
rna
stabil
reagent
rnalat
provid
qiagen
worldwid
compani
accord
express
respons
treatment
patient
psoriasi
manufactur
instruct
store
sampl
process
frozen
tissu
allow
thaw
handl
readi
quantit
pcr
determin
biopsi
weigh
process
biopsi
weigh
mg
effici
disrupt
homo
geniz
start
materi
perform
use
rotorst
homogen
total
rna
extract
use
qia
amp
rna
extract
kit
provid
qiagen
worldwid
compani
concentr
puriti
rna
determin
measur
absorb
nm
nm
uv
visibl
spectrophotomet
total
rna
reversetranscrib
cdna
highcapac
cdna
archiv
kit
provid
appli
biosystem
cdna
store
realtim
quantit
pcr
perform
realtim
quantit
pcr
perform
use
appli
biosystem
perkin
elmer
sequenc
detect
system
primer
sens
primer
aat
aaa
gat
ggc
tgc
tga
antisens
primer
cac
cac
aac
ctc
tac
ctc
pcr
reaction
volum
contain
taqman
univers
pcr
master
mix
nm
nm
forward
primer
nm
nm
revers
primer
nm
taqman
probe
label
fam
ng
ng
cdna
amplif
protocol
min
min
cycl
min
rel
gene
ex
pre
sion
determin
sampl
amplif
gene
dehydro
genas
gapdh
constitut
express
housekeep
gene
perform
sampl
gene
subsequ
normal
gapdh
level
studi
mrna
level
express
picogramsmicrolitr
data
collect
patient
chart
enter
computer
spreadsheet
fit
data
normal
distribut
test
kolmogorovsmirnov
test
sinc
distribut
data
significantli
differ
normal
nonparametr
statist
use
comparison
made
use
mannwhitney
u
kruskal
walli
wilcoxon
sign
rank
test
variabl
adjust
appropri
covari
spearman
rank
correl
coeffici
calcul
assess
variabl
null
hypothesi
reject
two
side
p
valu
analys
perform
spss
macintosh
statist
packag
social
scienc
spss
inc
chicago
il
usa
demograph
behaviour
characterist
includ
patient
present
tabl
pasi
score
use
evalu
sever
psoriasi
vari
mean
accord
ramsay
lawrenc
pasi
score
grade
differ
subtyp
psoriasi
demonstr
tabl
ii
patient
detect
level
mrna
uninvolv
skin
f
l
e
x
u
r
l
p
l
p
l
n
r
p
l
q
u
e
n
g
u
e
p
l
q
u
e
n
p
l
p
l
n
e
r
p
l
q
u
e
n
f
l
e
x
u
r
l
p
l
q
u
e
n
n
l
mean
sd
median
level
cytokin
gene
express
skin
biopsi
differ
time
receiv
medic
whether
topic
system
comparison
median
express
level
percentil
studi
patient
demonstr
figur
significantli
lower
express
uninvolv
skin
lesion
skin
treatment
p
lesion
skin
treatment
p
demonstr
studi
patient
one
group
express
psoriat
skin
lesion
treatment
significantli
lower
lesion
skin
treatment
p
mean
express
level
nonlesion
lesion
skin
treatment
differ
subtyp
psoriasi
shown
figur
highest
express
level
note
plaqu
nail
clinic
subtyp
psoriasi
among
patient
receiv
topic
steroid
significantli
lower
express
detect
nonlesion
skin
lesion
skin
treatment
p
treatment
p
statist
signific
could
obtain
compar
chang
express
topic
treatment
p
individu
variat
express
level
nonlesion
lesion
skin
ceiv
ing
topic
steroid
demonstr
figur
express
respons
treatment
patient
psoriasi
patient
receiv
methotrex
significantli
lower
express
detect
nonlesion
skin
lesion
skin
treatment
p
chang
express
level
lesion
skin
treatment
statist
signific
compar
nonlesion
skin
p
lesion
skin
treatment
p
individu
variat
express
level
nonlesion
lesion
skin
receiv
system
methotrex
demonstr
figur
correl
express
differ
demograph
behaviour
characterist
studi
patient
one
group
signific
correl
obtain
express
level
psoriat
lesion
sever
psoriasi
express
pasi
score
r
p
diseas
durat
r
p
signific
correl
could
reveal
express
level
psoriat
lesion
patient
age
smoke
state
predispos
factor
coexist
diseas
present
studi
patient
psoriasi
show
significantli
increas
express
keratinocyt
psoriat
lesion
receiv
medic
whether
topic
system
comparison
keratinocyt
nonlesion
skin
support
concept
psoriasi
cell
mediat
autoimmun
diseas
krueger
report
studi
larg
seri
skin
biopsi
increas
protein
express
lesion
oppos
nonlesion
skin
sampl
investig
state
lesion
skin
might
sourc
elev
plasma
level
present
work
quantit
pcr
use
mrna
taken
uninvolv
skin
reveal
low
detect
level
mrna
express
find
consist
previou
studi
show
human
keratinocyt
capabl
synthes
low
level
mrna
even
nonstimul
condit
chang
et
al
found
gene
specif
modul
uninvolv
skin
play
major
role
trigger
diseas
progress
first
candid
earli
diseas
diagnosi
develop
new
therapi
find
could
allow
select
treatment
regimen
individu
patient
present
studi
express
patient
receiv
topic
steroid
significantli
lower
nonlesion
skin
lesion
skin
treatment
month
treatment
express
level
return
back
low
valu
significantli
lower
lesion
skin
level
express
treatment
patient
receiv
methotrex
nonlesion
skin
express
significantli
lower
lesion
skin
treatment
also
express
level
decreas
treatment
still
statist
significantli
compar
lesion
skin
treatment
otkjaer
et
al
determin
nonlesion
lesion
psoriat
skin
day
treatment
use
topic
calcipotriol
ointment
mild
case
oral
cyclosporin
moder
sever
case
found
patient
treat
calcipotriol
mrna
express
level
lesion
psoriat
skin
reduc
day
reduct
becam
statist
signific
day
time
mrna
express
analysi
could
affect
degre
signific
support
studi
demonstr
decreas
level
narrowband
uvb
therapi
togeth
paramet
characterist
helper
respons
apart
stimul
respons
regul
respons
depend
local
cytokin
network
enhanc
product
induc
wherea
alon
induc
product
classic
system
treatment
psoriasi
fulli
met
need
patient
perman
improv
antibodybas
fusion
proteinbas
select
target
key
mediat
inflamm
ad
treatment
approach
psoriasi
kong
et
al
smeltz
studi
receptor
block
use
mous
keratinocyt
observ
express
level
decreas
synchron
treatment
tak
et
al
investig
bind
protein
bp
psoriat
patient
demonstr
bp
neutral
activ
studi
demonstr
express
psoriat
lesion
treatment
significantli
correl
sever
psoriasi
diseas
durat
correl
note
express
patient
age
smoke
statu
predispos
factor
coexist
diseas
flisiak
et
al
found
signific
correl
plasma
level
pasi
valu
find
correl
concentr
scale
pasi
score
trinquet
et
al
studi
influenc
diseas
durat
gene
express
profil
psoriasi
reveal
correl
howev
craven
et
al
studi
earli
late
onset
psoriasi
confirm
express
correl
significantli
diseas
durat
sampogna
et
al
studi
patient
psoriasi
find
signific
differ
older
younger
patient
regard
level
hand
chen
et
al
found
statist
signific
correl
express
level
age
p
valu
equal
conclus
base
increas
express
level
psoriat
skin
lesion
rel
uninvolv
skin
cytokin
appear
crucial
develop
activ
psoriat
lesion
produc
local
step
evolut
psoriat
lesion
could
support
correl
clinic
sever
diseas
durat
express
reduct
treatment
decreas
express
treatment
extent
indic
skin
return
normal
small
size
studi
popul
heterogen
group
patient
particip
studi
preclud
draw
firm
conclus
futur
studi
gene
involv
array
base
technolog
allow
confirm
result
also
studi
recommend
tri
line
treatment
psoriasi
one
line
therapi
tri
rh
bp
neutral
activ
wide
scale
may
ultim
lead
improv
outcom
patient
